Y
Yves Pommier
Researcher at National Institutes of Health
Publications - 847
Citations - 65543
Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.
Papers
More filters
Journal ArticleDOI
Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylation
Lőrinc S. Pongor,Camille Tlemsani,Fathi Elloumi,Yasuhiro Arakawa,Ukhyun Jo,Jacob M. Gross,Sara Mosavarpour,Sudhir Varma,Rahul K. Kollipara,Nitin Roper,Beverly A. Teicher,Mirit I. Aladjem,William C. Reinhold,Anish Thomas,John D. Minna,Jane E. Johnson,Yves Pommier +16 more
TL;DR: This paper examined global DNA methylation beyond the generally used promoter areas in human small cell lung cancer (SCLC) and find that gene body methylation is a robust positive predictor of gene expression.
Journal ArticleDOI
Studies of HIV Integrase Inhibitory Activity of Morinda citrifolia L Noni Fruit Extracts
Journal Article
Abstract #4664: Implication of ATM-/ATR-Chk1-E2F1-dependent up-regulation of ribonucleotide reductase R2 (RRM2) in DNA damage response
TL;DR: It is proposed that, upon DNA damage, Chk1 activation, mediated by ATM and ATR, regulates RRM2 expression through the E2F1 transcription factor, which suggests an active role for RNR in the cellular response to CPT-mediated DNA damage.
Journal ArticleDOI
Poly-adeninosinediphosphate-ribose polymerase inhibitors as sensitizers for therapeutic treatments in human tumor and blood mononuclear cells
Jiuping Ji,Christophe E. Redon,Yves Pommier,Robert J. Kinders,Ralph E. Parchment,Melinda G. Hollingshead,Sherry X. Yang,Anthony J. Murgo,Joseph E. Tomaszewski,James H. Doroshow +9 more
TL;DR: Treatment with single doses of ABT-888, a novel potent PARP-1 inhibitor, reduced PAR levels in peripheral blood mononuclear cells (PBMCs) and tumor biopsies in an on-going Phase-0 trial at the NIH Clinical Center.